U.S.-based Biogen Inc. (NASDAQ: BIIB) has announced a research collaboration with Neomorph to jointly develop molecular glue degraders targeting key areas in Alzheimer’s, rare neurological disorders, and immunological diseases.
Leveraging Neomorph’s proprietary molecular glue discovery platform, the partnership aims to enhance the identification and validation of novel small-molecule therapeutic degraders that effectively address challenging targets with distinct pharmacology compared to traditional inhibitors. The collaboration seeks to deliver innovative treatments for complex neurological, immunological, and rare diseases.
According to the agreement, Biogen and Neomorph will collaborate on the identification, validation, and optimization of small-molecule molecular glue degraders for several high-priority targets. Biogen will focus on advancing clinical candidates for further development and potential commercialization. Neomorph will receive an upfront payment and may earn contingent milestone payments for each target as the collaboration progresses, with notable pre-clinical milestones expected in the near term and additional clinical, regulatory, commercial, and sales milestones anticipated over the next decade, potentially totaling up to $1.45 billion. Furthermore, Biogen will reimburse Neomorph for certain research and development expenses, and Neomorph may also be eligible for potential future royalties ranging from mid-single digits to low double digits.- Flcube.com
